Recently added item(s)
You have no items in your basket.
You have probably heard a lot about CBD recently, whether at your local health food shop, on TV, or online, and for good reason! There has been a plethora of exciting research developments in this area in recent years and excitement about its potential continues to rise. Translating the latest research into cutting-edge, clinically effective products is at the heart of what we do here at BioCare®. We are therefore thrilled to introduce you to the latest addition to our product range - Liposomal CBD.
Hemp grown for industrial purposes, such as for the food industry, is naturally rich in a type of cannabinoid called cannabidiol (CBD) yet very low in the psychoactive, legally regulated compound, ∆9-tetrahydrocannabinol (∆9-THC).[i],[ii] Once thought to be the inactive cousin to the potent ∆9-THC, CBD has garnered a lot of attention following mainstream recognition of the results of decades’ worth of research, into its physiological benefits,[iii] which continues to develop at pace.[iv]
Liposomal technology is a way of optimising the bioavailability of an orally ingested substance (e.g. a nutrient) which is otherwise poorly absorbed into circulation, by packing it into a tiny structure called a liposome. A liposome is a sphere composed of a type of lipid called a phospholipid, which contains a small compartment where nutrients can be incorporated. This phospholipid ‘shell’ protects its special cargo and helps to carry the nutrients across the lining of the digestive tract. Once absorbed, the liposomes circulate around the body and are distributed to tissues and organs. Liposomes are deliberately made using the same phospholipids as our cell membranes, which means they can merge with them and deposit the contained nutrients directly into the cell.
Our use of liposomal technology is important as it circumvents well-established issues with the bioavailability of CBD.[vi] As little as 6% orally administered, straight (non-liposomal) CBD is absorbed by humans,[vii] principally due to poor intestinal absorption and extensive metabolism by the liver.[viii] In contrast, liposomal technology allows orally administered CBD to be up to 4x better absorbed than other oils and have an up to 3x longer-lasting effect according to pioneering preliminary research in humans.[ix] This striking difference means that the use of liposomal technology for CBD supplementation is an absolute must!
Not all liposomes are created equal though! The liposomal technology used to produce our Liposomal CBD is superior to others on the market because it:
The beauty of delivering CBD with superior bioavailability means that a lower daily dosage of CBD can have maximum effect. In fact, if liposomal CBD is around 4x better absorbed than standard, a 10mg daily dosage of liposomal CBD may deliver the biological activity of 40mg straight CBD, so it’s a far smarter way of supplementing CBD.
We hope you feel as excited about this product as we are! If you have any questions about how and when to use it, we encourage you to call or email our Clinical Nutrition team who are here to support you.
The brand you can talk to:
We have a team of Nutritionists at the end of our advice line, open to you, for product support and advice (5 days a week). 0121 433 8702 or firstname.lastname@example.org.
Not registered for an account with BioCare®?
[i] Sawler J et al. The genetic structure of marijuana and hemp. PLoS One. 2015; 10 (8): e0133292.
[ii] Yang Y et al. Cannabis sativa (hemp) seeds, ∆9-tetrahydrocannabinol, and potential overdose. Cannabis Cannabinoid Res. 2017; 2 (1): 274-281.
[iii] Crippa JA et al. Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. Front Immunol. 2018; 9: 2009.
[iv] Capano A et al. Evaluation of the effects of CBD hemp extract on opiod use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020; 132 (1): 56-61.
[v] Lucas CJ et al. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018; 84 (11): 2477-2482.
[vi] Millar SA et al. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018; 9: 1365.
[vii] Hawksworth, G, K. McArdle, Metabolism and pharmacokinetics of cannabinoids. The Medicinal Uses of Cannabis and Cannabinoids. Pharmaceutical Press, London, 2004: p. 205-228.
[viii] Ujváry I, Hanuš L. Human metabolites of Cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res. 2016; 1 (1): 90-101.
[ix] Knaub K et al. A novel self-emulsifying drug delivery system (SEDDS) based on VESIsorb® formulation technology improving the oral bioavailability of cannabidiol in healthy subjects. Molecules. 2019; 24 (16): E2967.